nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—CSNK1A1—esophageal cancer	0.258	0.393	CbGaD
Bosutinib—MAP3K3—esophageal cancer	0.179	0.273	CbGaD
Bosutinib—CHEK2—esophageal cancer	0.101	0.154	CbGaD
Bosutinib—ABL1—esophageal cancer	0.0662	0.101	CbGaD
Bosutinib—EGFR—esophageal cancer	0.0403	0.0613	CbGaD
Bosutinib—ABCB1—esophageal cancer	0.0123	0.0187	CbGaD
Bosutinib—Upper gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00324	0.0577	CcSEcCtD
Bosutinib—Gastrointestinal toxicity—Capecitabine—esophageal cancer	0.00227	0.0405	CcSEcCtD
Bosutinib—Gefitinib—SBK1—esophageal cancer	0.0022	0.443	CrCbGaD
Bosutinib—Bronchopneumonia—Capecitabine—esophageal cancer	0.00171	0.0305	CcSEcCtD
Bosutinib—Gastrointestinal toxicity—Methotrexate—esophageal cancer	0.00169	0.0302	CcSEcCtD
Bosutinib—Abdominal pain lower—Capecitabine—esophageal cancer	0.00117	0.0209	CcSEcCtD
Bosutinib—Lower respiratory tract infection—Capecitabine—esophageal cancer	0.00109	0.0195	CcSEcCtD
Bosutinib—Myelosuppression—Cisplatin—esophageal cancer	0.00108	0.0192	CcSEcCtD
Bosutinib—Amylase increased—Cisplatin—esophageal cancer	0.00106	0.019	CcSEcCtD
Bosutinib—Drug hypersensitivity—Capecitabine—esophageal cancer	0.000927	0.0165	CcSEcCtD
Bosutinib—Pericardial effusion—Capecitabine—esophageal cancer	0.00091	0.0162	CcSEcCtD
Bosutinib—Rash macular—Capecitabine—esophageal cancer	0.00091	0.0162	CcSEcCtD
Bosutinib—Hypophosphataemia—Cisplatin—esophageal cancer	0.000871	0.0155	CcSEcCtD
Bosutinib—Gefitinib—CHEK2—esophageal cancer	0.000858	0.173	CrCbGaD
Bosutinib—Febrile neutropenia—Cisplatin—esophageal cancer	0.000842	0.015	CcSEcCtD
Bosutinib—Prurigo—Capecitabine—esophageal cancer	0.000808	0.0144	CcSEcCtD
Bosutinib—Pericardial effusion—Methotrexate—esophageal cancer	0.000677	0.0121	CcSEcCtD
Bosutinib—Hepatotoxicity—Cisplatin—esophageal cancer	0.000656	0.0117	CcSEcCtD
Bosutinib—Pericarditis—Methotrexate—esophageal cancer	0.000642	0.0114	CcSEcCtD
Bosutinib—Febrile neutropenia—Capecitabine—esophageal cancer	0.00062	0.0111	CcSEcCtD
Bosutinib—Infection—Carboplatin—esophageal cancer	0.000612	0.0109	CcSEcCtD
Bosutinib—Liver injury—Cisplatin—esophageal cancer	0.000602	0.0107	CcSEcCtD
Bosutinib—Vandetanib—ABL1—esophageal cancer	0.000593	0.12	CrCbGaD
Bosutinib—Pain—Carboplatin—esophageal cancer	0.000527	0.00939	CcSEcCtD
Bosutinib—Vandetanib—KDR—esophageal cancer	0.000505	0.102	CrCbGaD
Bosutinib—Hyperkalaemia—Cisplatin—esophageal cancer	0.000497	0.00887	CcSEcCtD
Bosutinib—Pleural effusion—Capecitabine—esophageal cancer	0.000487	0.00869	CcSEcCtD
Bosutinib—Body temperature increased—Carboplatin—esophageal cancer	0.000487	0.00868	CcSEcCtD
Bosutinib—Hepatotoxicity—Capecitabine—esophageal cancer	0.000483	0.00861	CcSEcCtD
Bosutinib—Fluid retention—Cisplatin—esophageal cancer	0.000481	0.00857	CcSEcCtD
Bosutinib—Febrile neutropenia—Methotrexate—esophageal cancer	0.000462	0.00823	CcSEcCtD
Bosutinib—Chest discomfort—Capecitabine—esophageal cancer	0.000422	0.00752	CcSEcCtD
Bosutinib—Renal failure acute—Cisplatin—esophageal cancer	0.000398	0.00709	CcSEcCtD
Bosutinib—Blood bilirubin increased—Capecitabine—esophageal cancer	0.000395	0.00703	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.000368	0.00655	CcSEcCtD
Bosutinib—Pleural effusion—Methotrexate—esophageal cancer	0.000363	0.00647	CcSEcCtD
Bosutinib—Vandetanib—EGFR—esophageal cancer	0.000361	0.0727	CrCbGaD
Bosutinib—Hepatotoxicity—Methotrexate—esophageal cancer	0.00036	0.00641	CcSEcCtD
Bosutinib—Face oedema—Cisplatin—esophageal cancer	0.000355	0.00632	CcSEcCtD
Bosutinib—Fluid retention—Capecitabine—esophageal cancer	0.000354	0.00631	CcSEcCtD
Bosutinib—Blood creatinine increased—Cisplatin—esophageal cancer	0.000344	0.00614	CcSEcCtD
Bosutinib—Gefitinib—EGFR—esophageal cancer	0.000343	0.0691	CrCbGaD
Bosutinib—Dehydration—Cisplatin—esophageal cancer	0.000342	0.00609	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000331	0.0059	CcSEcCtD
Bosutinib—Nasopharyngitis—Cisplatin—esophageal cancer	0.000329	0.00586	CcSEcCtD
Bosutinib—CLK1—trachea—esophageal cancer	0.000316	0.00302	CbGeAlD
Bosutinib—ULK3—bronchus—esophageal cancer	0.000316	0.00302	CbGeAlD
Bosutinib—MAP2K2—bronchus—esophageal cancer	0.000316	0.00302	CbGeAlD
Bosutinib—EPHA3—lung—esophageal cancer	0.000314	0.00301	CbGeAlD
Bosutinib—PTK2—epithelium—esophageal cancer	0.000312	0.00299	CbGeAlD
Bosutinib—MAP3K7—bronchus—esophageal cancer	0.000311	0.00297	CbGeAlD
Bosutinib—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00031	0.00552	CcSEcCtD
Bosutinib—MAP2K2—smooth muscle tissue—esophageal cancer	0.000309	0.00296	CbGeAlD
Bosutinib—PLK2—lung—esophageal cancer	0.000308	0.00294	CbGeAlD
Bosutinib—PTK2—bronchus—esophageal cancer	0.000307	0.00294	CbGeAlD
Bosutinib—TBK1—bronchus—esophageal cancer	0.000307	0.00294	CbGeAlD
Bosutinib—ROCK1—digestive system—esophageal cancer	0.000307	0.00294	CbGeAlD
Bosutinib—SIK3—lung—esophageal cancer	0.000306	0.00292	CbGeAlD
Bosutinib—Abdominal discomfort—Cisplatin—esophageal cancer	0.000305	0.00543	CcSEcCtD
Bosutinib—MAP3K7—smooth muscle tissue—esophageal cancer	0.000304	0.00291	CbGeAlD
Bosutinib—Pancytopenia—Cisplatin—esophageal cancer	0.000302	0.00538	CcSEcCtD
Bosutinib—IRAK1—bronchus—esophageal cancer	0.000301	0.00288	CbGeAlD
Bosutinib—PTK2—smooth muscle tissue—esophageal cancer	0.000301	0.00288	CbGeAlD
Bosutinib—RPS6KB1—epithelium—esophageal cancer	0.0003	0.00287	CbGeAlD
Bosutinib—BMPR2—digestive system—esophageal cancer	0.000298	0.00285	CbGeAlD
Bosutinib—EPHB3—digestive system—esophageal cancer	0.000296	0.00283	CbGeAlD
Bosutinib—RPS6KB1—bronchus—esophageal cancer	0.000296	0.00283	CbGeAlD
Bosutinib—CSNK1E—trachea—esophageal cancer	0.000295	0.00282	CbGeAlD
Bosutinib—IRAK1—smooth muscle tissue—esophageal cancer	0.000295	0.00282	CbGeAlD
Bosutinib—STK4—lung—esophageal cancer	0.000294	0.00281	CbGeAlD
Bosutinib—LCK—bronchus—esophageal cancer	0.000294	0.00281	CbGeAlD
Bosutinib—Renal failure acute—Capecitabine—esophageal cancer	0.000293	0.00523	CcSEcCtD
Bosutinib—CAMK1D—lung—esophageal cancer	0.000291	0.00278	CbGeAlD
Bosutinib—IRAK4—trachea—esophageal cancer	0.00029	0.00278	CbGeAlD
Bosutinib—RPS6KB1—smooth muscle tissue—esophageal cancer	0.000289	0.00277	CbGeAlD
Bosutinib—STK24—lung—esophageal cancer	0.000287	0.00275	CbGeAlD
Bosutinib—EPHA4—trachea—esophageal cancer	0.000287	0.00275	CbGeAlD
Bosutinib—MAP4K4—digestive system—esophageal cancer	0.000287	0.00275	CbGeAlD
Bosutinib—AXL—smooth muscle tissue—esophageal cancer	0.000286	0.00274	CbGeAlD
Bosutinib—Renal impairment—Capecitabine—esophageal cancer	0.000285	0.00507	CcSEcCtD
Bosutinib—ERBB3—trachea—esophageal cancer	0.000284	0.00272	CbGeAlD
Bosutinib—EPHB4—epithelium—esophageal cancer	0.000284	0.00272	CbGeAlD
Bosutinib—ULK3—trachea—esophageal cancer	0.000284	0.00272	CbGeAlD
Bosutinib—TLK1—lymph node—esophageal cancer	0.000283	0.00271	CbGeAlD
Bosutinib—Respiratory failure—Methotrexate—esophageal cancer	0.000283	0.00504	CcSEcCtD
Bosutinib—PDGFRB—neck—esophageal cancer	0.000283	0.0027	CbGeAlD
Bosutinib—SLK—bronchus—esophageal cancer	0.000282	0.0027	CbGeAlD
Bosutinib—EPHB4—bronchus—esophageal cancer	0.00028	0.00268	CbGeAlD
Bosutinib—PRKCQ—lymph node—esophageal cancer	0.00028	0.00268	CbGeAlD
Bosutinib—MAP3K7—trachea—esophageal cancer	0.000279	0.00267	CbGeAlD
Bosutinib—EPHA2—epithelium—esophageal cancer	0.000279	0.00267	CbGeAlD
Bosutinib—Renal failure—Cisplatin—esophageal cancer	0.000278	0.00496	CcSEcCtD
Bosutinib—ALK—lung—esophageal cancer	0.000278	0.00266	CbGeAlD
Bosutinib—FER—lung—esophageal cancer	0.000278	0.00266	CbGeAlD
Bosutinib—MAP2K1—digestive system—esophageal cancer	0.000277	0.00265	CbGeAlD
Bosutinib—TBK1—trachea—esophageal cancer	0.000276	0.00264	CbGeAlD
Bosutinib—PTK2—trachea—esophageal cancer	0.000276	0.00264	CbGeAlD
Bosutinib—CSK—digestive system—esophageal cancer	0.000275	0.00264	CbGeAlD
Bosutinib—EPHA2—bronchus—esophageal cancer	0.000274	0.00263	CbGeAlD
Bosutinib—FYN—bronchus—esophageal cancer	0.000274	0.00262	CbGeAlD
Bosutinib—CSNK1A1—digestive system—esophageal cancer	0.000274	0.00262	CbGeAlD
Bosutinib—EPHB4—smooth muscle tissue—esophageal cancer	0.000274	0.00262	CbGeAlD
Bosutinib—MAP3K19—lung—esophageal cancer	0.000272	0.00261	CbGeAlD
Bosutinib—MAP4K1—lung—esophageal cancer	0.000272	0.00261	CbGeAlD
Bosutinib—HCK—digestive system—esophageal cancer	0.000272	0.0026	CbGeAlD
Bosutinib—CLK1—digestive system—esophageal cancer	0.000272	0.0026	CbGeAlD
Bosutinib—BTK—lung—esophageal cancer	0.000271	0.00259	CbGeAlD
Bosutinib—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000271	0.00483	CcSEcCtD
Bosutinib—FYN—smooth muscle tissue—esophageal cancer	0.000268	0.00256	CbGeAlD
Bosutinib—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000268	0.00477	CcSEcCtD
Bosutinib—MAP3K3—bronchus—esophageal cancer	0.000268	0.00256	CbGeAlD
Bosutinib—MAP4K5—bronchus—esophageal cancer	0.000268	0.00256	CbGeAlD
Bosutinib—TNK2—lung—esophageal cancer	0.000267	0.00256	CbGeAlD
Bosutinib—CAMK2G—digestive system—esophageal cancer	0.000267	0.00255	CbGeAlD
Bosutinib—RPS6KB1—trachea—esophageal cancer	0.000265	0.00254	CbGeAlD
Bosutinib—LCK—trachea—esophageal cancer	0.000264	0.00252	CbGeAlD
Bosutinib—MAP4K2—lung—esophageal cancer	0.000263	0.00252	CbGeAlD
Bosutinib—AXL—trachea—esophageal cancer	0.000263	0.00251	CbGeAlD
Bosutinib—DSTYK—lymph node—esophageal cancer	0.000262	0.00251	CbGeAlD
Bosutinib—BMX—lymph node—esophageal cancer	0.000262	0.00251	CbGeAlD
Bosutinib—CLK3—lymph node—esophageal cancer	0.000262	0.00251	CbGeAlD
Bosutinib—MAP4K5—smooth muscle tissue—esophageal cancer	0.000262	0.00251	CbGeAlD
Bosutinib—Face oedema—Capecitabine—esophageal cancer	0.000262	0.00466	CcSEcCtD
Bosutinib—ERBB4—lung—esophageal cancer	0.00026	0.00249	CbGeAlD
Bosutinib—STK3—lung—esophageal cancer	0.00026	0.00249	CbGeAlD
Bosutinib—BLK—lymph node—esophageal cancer	0.000259	0.00248	CbGeAlD
Bosutinib—PTK2B—digestive system—esophageal cancer	0.000258	0.00247	CbGeAlD
Bosutinib—ROCK1—lung—esophageal cancer	0.000256	0.00245	CbGeAlD
Bosutinib—PHKG1—lymph node—esophageal cancer	0.000256	0.00245	CbGeAlD
Bosutinib—CASK—lymph node—esophageal cancer	0.000256	0.00245	CbGeAlD
Bosutinib—Blood creatinine increased—Capecitabine—esophageal cancer	0.000254	0.00452	CcSEcCtD
Bosutinib—CSNK1E—digestive system—esophageal cancer	0.000254	0.00243	CbGeAlD
Bosutinib—EIF2AK1—lymph node—esophageal cancer	0.000254	0.00243	CbGeAlD
Bosutinib—SLK—trachea—esophageal cancer	0.000253	0.00242	CbGeAlD
Bosutinib—Dehydration—Capecitabine—esophageal cancer	0.000252	0.00449	CcSEcCtD
Bosutinib—EPHB4—trachea—esophageal cancer	0.000251	0.0024	CbGeAlD
Bosutinib—Urinary tract disorder—Cisplatin—esophageal cancer	0.000251	0.00447	CcSEcCtD
Bosutinib—Connective tissue disorder—Cisplatin—esophageal cancer	0.00025	0.00445	CcSEcCtD
Bosutinib—Urethral disorder—Cisplatin—esophageal cancer	0.000249	0.00444	CcSEcCtD
Bosutinib—BMPR2—lung—esophageal cancer	0.000249	0.00238	CbGeAlD
Bosutinib—TXK—lymph node—esophageal cancer	0.000248	0.00238	CbGeAlD
Bosutinib—Abdominal pain upper—Capecitabine—esophageal cancer	0.000247	0.00441	CcSEcCtD
Bosutinib—YES1—bronchus—esophageal cancer	0.000247	0.00237	CbGeAlD
Bosutinib—STK36—lung—esophageal cancer	0.000247	0.00237	CbGeAlD
Bosutinib—EPHB3—lung—esophageal cancer	0.000247	0.00237	CbGeAlD
Bosutinib—EPHA2—trachea—esophageal cancer	0.000246	0.00236	CbGeAlD
Bosutinib—FYN—trachea—esophageal cancer	0.000246	0.00235	CbGeAlD
Bosutinib—FES—lymph node—esophageal cancer	0.000246	0.00235	CbGeAlD
Bosutinib—VRK2—lymph node—esophageal cancer	0.000246	0.00235	CbGeAlD
Bosutinib—STK10—bronchus—esophageal cancer	0.000245	0.00234	CbGeAlD
Bosutinib—ERBB3—digestive system—esophageal cancer	0.000245	0.00234	CbGeAlD
Bosutinib—MERTK—lung—esophageal cancer	0.000244	0.00234	CbGeAlD
Bosutinib—ULK3—digestive system—esophageal cancer	0.000244	0.00234	CbGeAlD
Bosutinib—MAP2K2—digestive system—esophageal cancer	0.000244	0.00234	CbGeAlD
Bosutinib—TAOK3—bronchus—esophageal cancer	0.000244	0.00233	CbGeAlD
Bosutinib—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000244	0.00435	CcSEcCtD
Bosutinib—Nasopharyngitis—Capecitabine—esophageal cancer	0.000242	0.00432	CcSEcCtD
Bosutinib—YES1—smooth muscle tissue—esophageal cancer	0.000242	0.00231	CbGeAlD
Bosutinib—SRC—epithelium—esophageal cancer	0.000241	0.00231	CbGeAlD
Bosutinib—TNIK—lymph node—esophageal cancer	0.000241	0.00231	CbGeAlD
Bosutinib—SYK—lymph node—esophageal cancer	0.000241	0.00231	CbGeAlD
Bosutinib—MAP3K3—trachea—esophageal cancer	0.00024	0.0023	CbGeAlD
Bosutinib—MAP4K5—trachea—esophageal cancer	0.00024	0.0023	CbGeAlD
Bosutinib—MAP4K4—lung—esophageal cancer	0.00024	0.00229	CbGeAlD
Bosutinib—Gastritis—Capecitabine—esophageal cancer	0.00024	0.00427	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000239	0.00426	CcSEcCtD
Bosutinib—CDK2—lymph node—esophageal cancer	0.000239	0.00229	CbGeAlD
Bosutinib—BCR—lung—esophageal cancer	0.000238	0.00228	CbGeAlD
Bosutinib—NUAK2—lung—esophageal cancer	0.000238	0.00228	CbGeAlD
Bosutinib—PTK2—digestive system—esophageal cancer	0.000237	0.00227	CbGeAlD
Bosutinib—TBK1—digestive system—esophageal cancer	0.000237	0.00227	CbGeAlD
Bosutinib—Tinnitus—Cisplatin—esophageal cancer	0.000237	0.00422	CcSEcCtD
Bosutinib—STK26—lymph node—esophageal cancer	0.000237	0.00226	CbGeAlD
Bosutinib—MAP3K12—lung—esophageal cancer	0.000236	0.00226	CbGeAlD
Bosutinib—Cardiac disorder—Cisplatin—esophageal cancer	0.000236	0.00421	CcSEcCtD
Bosutinib—Influenza—Capecitabine—esophageal cancer	0.000234	0.00417	CcSEcCtD
Bosutinib—SRC—smooth muscle tissue—esophageal cancer	0.000233	0.00223	CbGeAlD
Bosutinib—STK35—lung—esophageal cancer	0.000232	0.00222	CbGeAlD
Bosutinib—MAP2K1—lung—esophageal cancer	0.000232	0.00222	CbGeAlD
Bosutinib—CSK—lung—esophageal cancer	0.00023	0.0022	CbGeAlD
Bosutinib—Immune system disorder—Cisplatin—esophageal cancer	0.00023	0.00409	CcSEcCtD
Bosutinib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000229	0.00408	CcSEcCtD
Bosutinib—CSNK1A1—lung—esophageal cancer	0.000229	0.00219	CbGeAlD
Bosutinib—CHEK2—lymph node—esophageal cancer	0.000229	0.00219	CbGeAlD
Bosutinib—RPS6KB1—digestive system—esophageal cancer	0.000228	0.00219	CbGeAlD
Bosutinib—HCK—lung—esophageal cancer	0.000227	0.00217	CbGeAlD
Bosutinib—CLK1—lung—esophageal cancer	0.000227	0.00217	CbGeAlD
Bosutinib—FGR—digestive system—esophageal cancer	0.000227	0.00217	CbGeAlD
Bosutinib—WEE1—lymph node—esophageal cancer	0.000227	0.00217	CbGeAlD
Bosutinib—DMPK—lymph node—esophageal cancer	0.000227	0.00217	CbGeAlD
Bosutinib—ABL2—lung—esophageal cancer	0.000226	0.00216	CbGeAlD
Bosutinib—Bronchitis—Capecitabine—esophageal cancer	0.000225	0.00401	CcSEcCtD
Bosutinib—Abdominal discomfort—Capecitabine—esophageal cancer	0.000224	0.004	CcSEcCtD
Bosutinib—CAMK2G—lung—esophageal cancer	0.000223	0.00213	CbGeAlD
Bosutinib—BMP2K—lung—esophageal cancer	0.000223	0.00213	CbGeAlD
Bosutinib—Pancytopenia—Capecitabine—esophageal cancer	0.000222	0.00396	CcSEcCtD
Bosutinib—YES1—trachea—esophageal cancer	0.000222	0.00212	CbGeAlD
Bosutinib—Malnutrition—Cisplatin—esophageal cancer	0.000221	0.00394	CcSEcCtD
Bosutinib—LRRK2—lung—esophageal cancer	0.000221	0.00211	CbGeAlD
Bosutinib—EGFR—lung—esophageal cancer	0.00022	0.00211	CbGeAlD
Bosutinib—TAOK3—trachea—esophageal cancer	0.000219	0.0021	CbGeAlD
Bosutinib—Neutropenia—Capecitabine—esophageal cancer	0.000219	0.0039	CcSEcCtD
Bosutinib—MAP2K5—bronchus—esophageal cancer	0.000219	0.00209	CbGeAlD
Bosutinib—Renal failure acute—Methotrexate—esophageal cancer	0.000218	0.00389	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000218	0.00388	CcSEcCtD
Bosutinib—STK25—lymph node—esophageal cancer	0.000216	0.00207	CbGeAlD
Bosutinib—EPHB4—digestive system—esophageal cancer	0.000216	0.00207	CbGeAlD
Bosutinib—PTK2B—lung—esophageal cancer	0.000215	0.00206	CbGeAlD
Bosutinib—EPHA3—lymph node—esophageal cancer	0.000215	0.00206	CbGeAlD
Bosutinib—CSF1R—bronchus—esophageal cancer	0.000213	0.00204	CbGeAlD
Bosutinib—EPHA2—digestive system—esophageal cancer	0.000212	0.00203	CbGeAlD
Bosutinib—CSNK1E—lung—esophageal cancer	0.000212	0.00203	CbGeAlD
Bosutinib—FYN—digestive system—esophageal cancer	0.000212	0.00202	CbGeAlD
Bosutinib—PLK2—lymph node—esophageal cancer	0.00021	0.00201	CbGeAlD
Bosutinib—Pneumonia—Capecitabine—esophageal cancer	0.00021	0.00374	CcSEcCtD
Bosutinib—SIK3—lymph node—esophageal cancer	0.000209	0.002	CbGeAlD
Bosutinib—CSF1R—smooth muscle tissue—esophageal cancer	0.000209	0.002	CbGeAlD
Bosutinib—Infestation NOS—Capecitabine—esophageal cancer	0.000209	0.00372	CcSEcCtD
Bosutinib—Infestation—Capecitabine—esophageal cancer	0.000209	0.00372	CcSEcCtD
Bosutinib—SIK1—lung—esophageal cancer	0.000209	0.002	CbGeAlD
Bosutinib—IRAK4—lung—esophageal cancer	0.000209	0.002	CbGeAlD
Bosutinib—EPHA4—lung—esophageal cancer	0.000206	0.00198	CbGeAlD
Bosutinib—Ill-defined disorder—Cisplatin—esophageal cancer	0.000205	0.00366	CcSEcCtD
Bosutinib—Renal failure—Capecitabine—esophageal cancer	0.000205	0.00366	CcSEcCtD
Bosutinib—Anaemia—Cisplatin—esophageal cancer	0.000205	0.00365	CcSEcCtD
Bosutinib—ERBB3—lung—esophageal cancer	0.000204	0.00196	CbGeAlD
Bosutinib—ULK3—lung—esophageal cancer	0.000204	0.00195	CbGeAlD
Bosutinib—MAP2K2—lung—esophageal cancer	0.000204	0.00195	CbGeAlD
Bosutinib—MAP3K2—lung—esophageal cancer	0.000202	0.00194	CbGeAlD
Bosutinib—STK4—lymph node—esophageal cancer	0.000201	0.00193	CbGeAlD
Bosutinib—MAP3K7—lung—esophageal cancer	0.000201	0.00192	CbGeAlD
Bosutinib—Malaise—Cisplatin—esophageal cancer	0.0002	0.00356	CcSEcCtD
Bosutinib—CAMK1D—lymph node—esophageal cancer	0.000199	0.0019	CbGeAlD
Bosutinib—PTK2—lung—esophageal cancer	0.000198	0.0019	CbGeAlD
Bosutinib—TBK1—lung—esophageal cancer	0.000198	0.0019	CbGeAlD
Bosutinib—Leukopenia—Cisplatin—esophageal cancer	0.000198	0.00353	CcSEcCtD
Bosutinib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000197	0.00352	CcSEcCtD
Bosutinib—STK24—lymph node—esophageal cancer	0.000196	0.00188	CbGeAlD
Bosutinib—MAP2K5—trachea—esophageal cancer	0.000196	0.00188	CbGeAlD
Bosutinib—Agranulocytosis—Capecitabine—esophageal cancer	0.000195	0.00347	CcSEcCtD
Bosutinib—IRAK1—lung—esophageal cancer	0.000194	0.00186	CbGeAlD
Bosutinib—PDGFRB—epithelium—esophageal cancer	0.000192	0.00184	CbGeAlD
Bosutinib—CSF1R—trachea—esophageal cancer	0.000192	0.00183	CbGeAlD
Bosutinib—YES1—digestive system—esophageal cancer	0.000191	0.00183	CbGeAlD
Bosutinib—RPS6KB1—lung—esophageal cancer	0.000191	0.00183	CbGeAlD
Bosutinib—ALK—lymph node—esophageal cancer	0.00019	0.00182	CbGeAlD
Bosutinib—FER—lymph node—esophageal cancer	0.00019	0.00182	CbGeAlD
Bosutinib—LCK—lung—esophageal cancer	0.00019	0.00181	CbGeAlD
Bosutinib—FGR—lung—esophageal cancer	0.00019	0.00181	CbGeAlD
Bosutinib—PDGFRB—bronchus—esophageal cancer	0.000189	0.00181	CbGeAlD
Bosutinib—STK10—digestive system—esophageal cancer	0.000189	0.00181	CbGeAlD
Bosutinib—AXL—lung—esophageal cancer	0.000189	0.00181	CbGeAlD
Bosutinib—TAOK3—digestive system—esophageal cancer	0.000188	0.0018	CbGeAlD
Bosutinib—Myalgia—Cisplatin—esophageal cancer	0.000188	0.00336	CcSEcCtD
Bosutinib—Hepatitis—Capecitabine—esophageal cancer	0.000187	0.00334	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000187	0.00333	CcSEcCtD
Bosutinib—MAP4K1—lymph node—esophageal cancer	0.000186	0.00178	CbGeAlD
Bosutinib—Discomfort—Cisplatin—esophageal cancer	0.000186	0.00332	CcSEcCtD
Bosutinib—BTK—lymph node—esophageal cancer	0.000185	0.00177	CbGeAlD
Bosutinib—PDGFRB—smooth muscle tissue—esophageal cancer	0.000185	0.00177	CbGeAlD
Bosutinib—Urinary tract disorder—Capecitabine—esophageal cancer	0.000185	0.0033	CcSEcCtD
Bosutinib—Oedema peripheral—Capecitabine—esophageal cancer	0.000185	0.00329	CcSEcCtD
Bosutinib—Connective tissue disorder—Capecitabine—esophageal cancer	0.000184	0.00328	CcSEcCtD
Bosutinib—Urethral disorder—Capecitabine—esophageal cancer	0.000184	0.00327	CcSEcCtD
Bosutinib—SRC—digestive system—esophageal cancer	0.000184	0.00176	CbGeAlD
Bosutinib—TNK2—lymph node—esophageal cancer	0.000183	0.00175	CbGeAlD
Bosutinib—SLK—lung—esophageal cancer	0.000182	0.00174	CbGeAlD
Bosutinib—Oedema—Cisplatin—esophageal cancer	0.000181	0.00322	CcSEcCtD
Bosutinib—Anaphylactic shock—Cisplatin—esophageal cancer	0.000181	0.00322	CcSEcCtD
Bosutinib—EPHB4—lung—esophageal cancer	0.00018	0.00173	CbGeAlD
Bosutinib—MAP4K2—lymph node—esophageal cancer	0.00018	0.00172	CbGeAlD
Bosutinib—Infection—Cisplatin—esophageal cancer	0.000179	0.0032	CcSEcCtD
Bosutinib—STK3—lymph node—esophageal cancer	0.000178	0.0017	CbGeAlD
Bosutinib—Erythema multiforme—Capecitabine—esophageal cancer	0.000177	0.00316	CcSEcCtD
Bosutinib—Nervous system disorder—Cisplatin—esophageal cancer	0.000177	0.00316	CcSEcCtD
Bosutinib—EPHA2—lung—esophageal cancer	0.000177	0.00169	CbGeAlD
Bosutinib—Thrombocytopenia—Cisplatin—esophageal cancer	0.000177	0.00315	CcSEcCtD
Bosutinib—FYN—lung—esophageal cancer	0.000177	0.00169	CbGeAlD
Bosutinib—Skin disorder—Cisplatin—esophageal cancer	0.000175	0.00313	CcSEcCtD
Bosutinib—Tinnitus—Capecitabine—esophageal cancer	0.000175	0.00311	CcSEcCtD
Bosutinib—Cardiac disorder—Capecitabine—esophageal cancer	0.000174	0.0031	CcSEcCtD
Bosutinib—MAP3K3—lung—esophageal cancer	0.000173	0.00165	CbGeAlD
Bosutinib—MAP4K5—lung—esophageal cancer	0.000173	0.00165	CbGeAlD
Bosutinib—BMPR2—lymph node—esophageal cancer	0.00017	0.00163	CbGeAlD
Bosutinib—PDGFRB—trachea—esophageal cancer	0.00017	0.00163	CbGeAlD
Bosutinib—Immune system disorder—Capecitabine—esophageal cancer	0.000169	0.00302	CcSEcCtD
Bosutinib—EPHB3—lymph node—esophageal cancer	0.000169	0.00162	CbGeAlD
Bosutinib—STK36—lymph node—esophageal cancer	0.000169	0.00162	CbGeAlD
Bosutinib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000169	0.00301	CcSEcCtD
Bosutinib—ABL1—bronchus—esophageal cancer	0.000169	0.00161	CbGeAlD
Bosutinib—Abdominal discomfort—Methotrexate—esophageal cancer	0.000167	0.00298	CcSEcCtD
Bosutinib—MERTK—lymph node—esophageal cancer	0.000167	0.0016	CbGeAlD
Bosutinib—Pancytopenia—Methotrexate—esophageal cancer	0.000166	0.00295	CcSEcCtD
Bosutinib—ABL1—smooth muscle tissue—esophageal cancer	0.000165	0.00158	CbGeAlD
Bosutinib—CSF1R—digestive system—esophageal cancer	0.000165	0.00158	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000165	0.00293	CcSEcCtD
Bosutinib—MAP4K4—lymph node—esophageal cancer	0.000164	0.00157	CbGeAlD
Bosutinib—Malnutrition—Capecitabine—esophageal cancer	0.000163	0.00291	CcSEcCtD
Bosutinib—Neutropenia—Methotrexate—esophageal cancer	0.000163	0.0029	CcSEcCtD
Bosutinib—BCR—lymph node—esophageal cancer	0.000163	0.00156	CbGeAlD
Bosutinib—NUAK2—lymph node—esophageal cancer	0.000163	0.00156	CbGeAlD
Bosutinib—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000162	0.00289	CcSEcCtD
Bosutinib—MAP3K12—lymph node—esophageal cancer	0.000162	0.00155	CbGeAlD
Bosutinib—Dyspnoea—Cisplatin—esophageal cancer	0.000161	0.00287	CcSEcCtD
Bosutinib—Dysgeusia—Capecitabine—esophageal cancer	0.00016	0.00285	CcSEcCtD
Bosutinib—YES1—lung—esophageal cancer	0.000159	0.00153	CbGeAlD
Bosutinib—STK35—lymph node—esophageal cancer	0.000158	0.00152	CbGeAlD
Bosutinib—MAP2K1—lymph node—esophageal cancer	0.000158	0.00152	CbGeAlD
Bosutinib—STK10—lung—esophageal cancer	0.000158	0.00151	CbGeAlD
Bosutinib—Back pain—Capecitabine—esophageal cancer	0.000158	0.00281	CcSEcCtD
Bosutinib—TAOK3—lung—esophageal cancer	0.000157	0.00151	CbGeAlD
Bosutinib—CSK—lymph node—esophageal cancer	0.000157	0.00151	CbGeAlD
Bosutinib—Decreased appetite—Cisplatin—esophageal cancer	0.000157	0.0028	CcSEcCtD
Bosutinib—CSNK1A1—lymph node—esophageal cancer	0.000156	0.0015	CbGeAlD
Bosutinib—Pneumonia—Methotrexate—esophageal cancer	0.000156	0.00279	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000156	0.00278	CcSEcCtD
Bosutinib—Infestation—Methotrexate—esophageal cancer	0.000155	0.00277	CcSEcCtD
Bosutinib—Infestation NOS—Methotrexate—esophageal cancer	0.000155	0.00277	CcSEcCtD
Bosutinib—HCK—lymph node—esophageal cancer	0.000155	0.00149	CbGeAlD
Bosutinib—CLK1—lymph node—esophageal cancer	0.000155	0.00149	CbGeAlD
Bosutinib—Pain—Cisplatin—esophageal cancer	0.000154	0.00275	CcSEcCtD
Bosutinib—ABL2—lymph node—esophageal cancer	0.000154	0.00148	CbGeAlD
Bosutinib—SRC—lung—esophageal cancer	0.000153	0.00147	CbGeAlD
Bosutinib—Renal failure—Methotrexate—esophageal cancer	0.000153	0.00272	CcSEcCtD
Bosutinib—BMP2K—lymph node—esophageal cancer	0.000152	0.00146	CbGeAlD
Bosutinib—CAMK2G—lymph node—esophageal cancer	0.000152	0.00146	CbGeAlD
Bosutinib—ABL1—trachea—esophageal cancer	0.000152	0.00145	CbGeAlD
Bosutinib—Ill-defined disorder—Capecitabine—esophageal cancer	0.000151	0.0027	CcSEcCtD
Bosutinib—LRRK2—lymph node—esophageal cancer	0.000151	0.00145	CbGeAlD
Bosutinib—Anaemia—Capecitabine—esophageal cancer	0.000151	0.00269	CcSEcCtD
Bosutinib—EGFR—lymph node—esophageal cancer	0.000151	0.00144	CbGeAlD
Bosutinib—Feeling abnormal—Cisplatin—esophageal cancer	0.000149	0.00265	CcSEcCtD
Bosutinib—PTK2B—lymph node—esophageal cancer	0.000147	0.00141	CbGeAlD
Bosutinib—Malaise—Capecitabine—esophageal cancer	0.000147	0.00262	CcSEcCtD
Bosutinib—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000147	0.00262	CcSEcCtD
Bosutinib—PDGFRB—digestive system—esophageal cancer	0.000146	0.0014	CbGeAlD
Bosutinib—Leukopenia—Capecitabine—esophageal cancer	0.000146	0.0026	CcSEcCtD
Bosutinib—Agranulocytosis—Methotrexate—esophageal cancer	0.000145	0.00258	CcSEcCtD
Bosutinib—CSNK1E—lymph node—esophageal cancer	0.000145	0.00139	CbGeAlD
Bosutinib—Body temperature increased—Cisplatin—esophageal cancer	0.000143	0.00254	CcSEcCtD
Bosutinib—SIK1—lymph node—esophageal cancer	0.000143	0.00136	CbGeAlD
Bosutinib—IRAK4—lymph node—esophageal cancer	0.000143	0.00136	CbGeAlD
Bosutinib—Cough—Capecitabine—esophageal cancer	0.000142	0.00254	CcSEcCtD
Bosutinib—EPHA4—lymph node—esophageal cancer	0.000141	0.00135	CbGeAlD
Bosutinib—MAP2K5—lung—esophageal cancer	0.000141	0.00135	CbGeAlD
Bosutinib—ERBB3—lymph node—esophageal cancer	0.00014	0.00134	CbGeAlD
Bosutinib—Hepatitis—Methotrexate—esophageal cancer	0.00014	0.00249	CcSEcCtD
Bosutinib—ULK3—lymph node—esophageal cancer	0.000139	0.00133	CbGeAlD
Bosutinib—MAP2K2—lymph node—esophageal cancer	0.000139	0.00133	CbGeAlD
Bosutinib—Chest pain—Capecitabine—esophageal cancer	0.000139	0.00248	CcSEcCtD
Bosutinib—Myalgia—Capecitabine—esophageal cancer	0.000139	0.00248	CcSEcCtD
Bosutinib—Arthralgia—Capecitabine—esophageal cancer	0.000139	0.00248	CcSEcCtD
Bosutinib—MAP3K2—lymph node—esophageal cancer	0.000138	0.00132	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000138	0.00246	CcSEcCtD
Bosutinib—Urinary tract disorder—Methotrexate—esophageal cancer	0.000138	0.00246	CcSEcCtD
Bosutinib—CSF1R—lung—esophageal cancer	0.000138	0.00132	CbGeAlD
Bosutinib—Discomfort—Capecitabine—esophageal cancer	0.000137	0.00245	CcSEcCtD
Bosutinib—MAP3K7—lymph node—esophageal cancer	0.000137	0.00131	CbGeAlD
Bosutinib—Urethral disorder—Methotrexate—esophageal cancer	0.000137	0.00244	CcSEcCtD
Bosutinib—TBK1—lymph node—esophageal cancer	0.000136	0.0013	CbGeAlD
Bosutinib—PTK2—lymph node—esophageal cancer	0.000136	0.0013	CbGeAlD
Bosutinib—Oedema—Capecitabine—esophageal cancer	0.000133	0.00237	CcSEcCtD
Bosutinib—IRAK1—lymph node—esophageal cancer	0.000133	0.00127	CbGeAlD
Bosutinib—Infection—Capecitabine—esophageal cancer	0.000132	0.00236	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—esophageal cancer	0.000132	0.00235	CcSEcCtD
Bosutinib—Nervous system disorder—Capecitabine—esophageal cancer	0.000131	0.00233	CcSEcCtD
Bosutinib—RPS6KB1—lymph node—esophageal cancer	0.00013	0.00125	CbGeAlD
Bosutinib—Thrombocytopenia—Capecitabine—esophageal cancer	0.00013	0.00232	CcSEcCtD
Bosutinib—ABL1—digestive system—esophageal cancer	0.00013	0.00125	CbGeAlD
Bosutinib—Tinnitus—Methotrexate—esophageal cancer	0.00013	0.00232	CcSEcCtD
Bosutinib—LCK—lymph node—esophageal cancer	0.00013	0.00124	CbGeAlD
Bosutinib—FGR—lymph node—esophageal cancer	0.00013	0.00124	CbGeAlD
Bosutinib—Asthenia—Cisplatin—esophageal cancer	0.00013	0.00231	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—esophageal cancer	0.000129	0.00231	CcSEcCtD
Bosutinib—Skin disorder—Capecitabine—esophageal cancer	0.000129	0.0023	CcSEcCtD
Bosutinib—AXL—lymph node—esophageal cancer	0.000129	0.00124	CbGeAlD
Bosutinib—Immune system disorder—Methotrexate—esophageal cancer	0.000126	0.00225	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—esophageal cancer	0.000126	0.00224	CcSEcCtD
Bosutinib—SLK—lymph node—esophageal cancer	0.000124	0.00119	CbGeAlD
Bosutinib—Diarrhoea—Cisplatin—esophageal cancer	0.000124	0.0022	CcSEcCtD
Bosutinib—EPHB4—lymph node—esophageal cancer	0.000123	0.00118	CbGeAlD
Bosutinib—PDGFRB—lung—esophageal cancer	0.000122	0.00117	CbGeAlD
Bosutinib—Malnutrition—Methotrexate—esophageal cancer	0.000121	0.00216	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000121	0.00216	CcSEcCtD
Bosutinib—EPHA2—lymph node—esophageal cancer	0.000121	0.00116	CbGeAlD
Bosutinib—FYN—lymph node—esophageal cancer	0.000121	0.00116	CbGeAlD
Bosutinib—Dysgeusia—Methotrexate—esophageal cancer	0.000119	0.00212	CcSEcCtD
Bosutinib—Dyspnoea—Capecitabine—esophageal cancer	0.000119	0.00212	CcSEcCtD
Bosutinib—MAP4K5—lymph node—esophageal cancer	0.000118	0.00113	CbGeAlD
Bosutinib—MAP3K3—lymph node—esophageal cancer	0.000118	0.00113	CbGeAlD
Bosutinib—Back pain—Methotrexate—esophageal cancer	0.000117	0.00209	CcSEcCtD
Bosutinib—Decreased appetite—Capecitabine—esophageal cancer	0.000116	0.00206	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000115	0.00205	CcSEcCtD
Bosutinib—Vomiting—Cisplatin—esophageal cancer	0.000115	0.00205	CcSEcCtD
Bosutinib—Fatigue—Capecitabine—esophageal cancer	0.000115	0.00205	CcSEcCtD
Bosutinib—Rash—Cisplatin—esophageal cancer	0.000114	0.00203	CcSEcCtD
Bosutinib—Pain—Capecitabine—esophageal cancer	0.000114	0.00203	CcSEcCtD
Bosutinib—Dermatitis—Cisplatin—esophageal cancer	0.000114	0.00203	CcSEcCtD
Bosutinib—Ill-defined disorder—Methotrexate—esophageal cancer	0.000113	0.00201	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—esophageal cancer	0.000112	0.002	CcSEcCtD
Bosutinib—Feeling abnormal—Capecitabine—esophageal cancer	0.00011	0.00196	CcSEcCtD
Bosutinib—Malaise—Methotrexate—esophageal cancer	0.00011	0.00195	CcSEcCtD
Bosutinib—YES1—lymph node—esophageal cancer	0.000109	0.00104	CbGeAlD
Bosutinib—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000109	0.00194	CcSEcCtD
Bosutinib—ABL1—lung—esophageal cancer	0.000109	0.00104	CbGeAlD
Bosutinib—Leukopenia—Methotrexate—esophageal cancer	0.000109	0.00194	CcSEcCtD
Bosutinib—STK10—lymph node—esophageal cancer	0.000108	0.00103	CbGeAlD
Bosutinib—TAOK3—lymph node—esophageal cancer	0.000108	0.00103	CbGeAlD
Bosutinib—Nausea—Cisplatin—esophageal cancer	0.000107	0.00191	CcSEcCtD
Bosutinib—Cough—Methotrexate—esophageal cancer	0.000106	0.00189	CcSEcCtD
Bosutinib—Urticaria—Capecitabine—esophageal cancer	0.000106	0.00189	CcSEcCtD
Bosutinib—Body temperature increased—Capecitabine—esophageal cancer	0.000105	0.00188	CcSEcCtD
Bosutinib—Abdominal pain—Capecitabine—esophageal cancer	0.000105	0.00188	CcSEcCtD
Bosutinib—SRC—lymph node—esophageal cancer	0.000105	0.001	CbGeAlD
Bosutinib—Gefitinib—ABCB1—esophageal cancer	0.000104	0.021	CrCbGaD
Bosutinib—Chest pain—Methotrexate—esophageal cancer	0.000103	0.00184	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—esophageal cancer	0.000103	0.00184	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—esophageal cancer	0.000103	0.00184	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000103	0.00183	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—esophageal cancer	0.000102	0.00182	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—esophageal cancer	9.91e-05	0.00177	CcSEcCtD
Bosutinib—Infection—Methotrexate—esophageal cancer	9.85e-05	0.00175	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—esophageal cancer	9.72e-05	0.00173	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—esophageal cancer	9.7e-05	0.00173	CcSEcCtD
Bosutinib—MAP2K5—lymph node—esophageal cancer	9.65e-05	0.000924	CbGeAlD
Bosutinib—Skin disorder—Methotrexate—esophageal cancer	9.63e-05	0.00172	CcSEcCtD
Bosutinib—Asthenia—Capecitabine—esophageal cancer	9.55e-05	0.0017	CcSEcCtD
Bosutinib—Pruritus—Capecitabine—esophageal cancer	9.42e-05	0.00168	CcSEcCtD
Bosutinib—CSF1R—lymph node—esophageal cancer	9.42e-05	0.000901	CbGeAlD
Bosutinib—Diarrhoea—Capecitabine—esophageal cancer	9.11e-05	0.00162	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	9.03e-05	0.00161	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—esophageal cancer	8.84e-05	0.00157	CcSEcCtD
Bosutinib—Dizziness—Capecitabine—esophageal cancer	8.8e-05	0.00157	CcSEcCtD
Bosutinib—Decreased appetite—Methotrexate—esophageal cancer	8.62e-05	0.00154	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—esophageal cancer	8.56e-05	0.00153	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—esophageal cancer	8.55e-05	0.00152	CcSEcCtD
Bosutinib—Pain—Methotrexate—esophageal cancer	8.48e-05	0.00151	CcSEcCtD
Bosutinib—Vomiting—Capecitabine—esophageal cancer	8.47e-05	0.00151	CcSEcCtD
Bosutinib—Rash—Capecitabine—esophageal cancer	8.4e-05	0.0015	CcSEcCtD
Bosutinib—Dermatitis—Capecitabine—esophageal cancer	8.39e-05	0.00149	CcSEcCtD
Bosutinib—PDGFRB—lymph node—esophageal cancer	8.35e-05	0.000799	CbGeAlD
Bosutinib—Headache—Capecitabine—esophageal cancer	8.34e-05	0.00149	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—esophageal cancer	8.17e-05	0.00146	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—esophageal cancer	8.11e-05	0.00144	CcSEcCtD
Bosutinib—Nausea—Capecitabine—esophageal cancer	7.91e-05	0.00141	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—esophageal cancer	7.87e-05	0.0014	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—esophageal cancer	7.84e-05	0.0014	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—esophageal cancer	7.84e-05	0.0014	CcSEcCtD
Bosutinib—ABL1—lymph node—esophageal cancer	7.45e-05	0.000713	CbGeAlD
Bosutinib—Asthenia—Methotrexate—esophageal cancer	7.11e-05	0.00127	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—esophageal cancer	7.01e-05	0.00125	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—esophageal cancer	6.78e-05	0.00121	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—esophageal cancer	6.55e-05	0.00117	CcSEcCtD
Bosutinib—Vomiting—Methotrexate—esophageal cancer	6.3e-05	0.00112	CcSEcCtD
Bosutinib—Rash—Methotrexate—esophageal cancer	6.25e-05	0.00111	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—esophageal cancer	6.24e-05	0.00111	CcSEcCtD
Bosutinib—Headache—Methotrexate—esophageal cancer	6.21e-05	0.00111	CcSEcCtD
Bosutinib—Nausea—Methotrexate—esophageal cancer	5.89e-05	0.00105	CcSEcCtD
Bosutinib—CYP3A4—digestive system—esophageal cancer	5.73e-05	0.000548	CbGeAlD
Bosutinib—ABCB1—epithelium—esophageal cancer	5.33e-05	0.00051	CbGeAlD
Bosutinib—ABCB1—trachea—esophageal cancer	4.71e-05	0.000451	CbGeAlD
Bosutinib—ABCB1—digestive system—esophageal cancer	4.05e-05	0.000388	CbGeAlD
Bosutinib—ABCB1—lung—esophageal cancer	3.39e-05	0.000324	CbGeAlD
Bosutinib—ABCB1—lymph node—esophageal cancer	2.32e-05	0.000222	CbGeAlD
Bosutinib—FYN—Immune System—EP300—esophageal cancer	8.92e-07	5.02e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CREBBP—esophageal cancer	8.91e-07	5.02e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—EP300—esophageal cancer	8.87e-07	4.99e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TYMP—esophageal cancer	8.85e-07	4.98e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MYC—esophageal cancer	8.85e-07	4.98e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—EGFR—esophageal cancer	8.85e-07	4.98e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CREBBP—esophageal cancer	8.78e-07	4.95e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—EP300—esophageal cancer	8.76e-07	4.93e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—ERBB2—esophageal cancer	8.75e-07	4.92e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MYC—esophageal cancer	8.72e-07	4.91e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—PIK3CA—esophageal cancer	8.69e-07	4.89e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—CDKN1A—esophageal cancer	8.66e-07	4.87e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CCND1—esophageal cancer	8.65e-07	4.87e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—EGFR—esophageal cancer	8.65e-07	4.87e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HIF1A—esophageal cancer	8.63e-07	4.86e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—ERBB2—esophageal cancer	8.63e-07	4.86e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—CDKN1A—esophageal cancer	8.61e-07	4.85e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	8.61e-07	4.84e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CREBBP—esophageal cancer	8.6e-07	4.84e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KDR—esophageal cancer	8.57e-07	4.82e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PTGS2—esophageal cancer	8.55e-07	4.82e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—EP300—esophageal cancer	8.54e-07	4.81e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CCND1—esophageal cancer	8.53e-07	4.8e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—EGFR—esophageal cancer	8.53e-07	4.8e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—PIK3CA—esophageal cancer	8.53e-07	4.8e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CREBBP—esophageal cancer	8.47e-07	4.77e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—ERBB2—esophageal cancer	8.43e-07	4.75e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CREBBP—esophageal cancer	8.42e-07	4.74e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—esophageal cancer	8.41e-07	4.73e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MYC—esophageal cancer	8.4e-07	4.73e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALOX15—esophageal cancer	8.39e-07	4.72e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CDKN1A—esophageal cancer	8.37e-07	4.71e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—PIK3CA—esophageal cancer	8.35e-07	4.7e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—BCL2—esophageal cancer	8.32e-07	4.68e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—EGFR—esophageal cancer	8.28e-07	4.66e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CDKN1A—esophageal cancer	8.26e-07	4.65e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KDR—esophageal cancer	8.25e-07	4.65e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PTGS2—esophageal cancer	8.24e-07	4.64e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—EP300—esophageal cancer	8.24e-07	4.64e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—EGFR—esophageal cancer	8.21e-07	4.62e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EP300—esophageal cancer	8.19e-07	4.61e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CDKN1A—esophageal cancer	8.1e-07	4.56e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CCND1—esophageal cancer	8.09e-07	4.56e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MYC—esophageal cancer	8.09e-07	4.55e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MYC—esophageal cancer	8.09e-07	4.55e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—ERBB2—esophageal cancer	8.08e-07	4.55e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—EGFR—esophageal cancer	8.08e-07	4.55e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NOTCH1—esophageal cancer	8.07e-07	4.54e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NOS3—esophageal cancer	8.06e-07	4.54e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—PIK3CA—esophageal cancer	8.03e-07	4.52e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CYP1B1—esophageal cancer	8.02e-07	4.52e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—PIK3CA—esophageal cancer	8.02e-07	4.51e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTO1—esophageal cancer	8e-07	4.5e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TPI1—esophageal cancer	8e-07	4.5e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—NOS3—esophageal cancer	7.98e-07	4.49e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EP300—esophageal cancer	7.97e-07	4.48e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—EGFR—esophageal cancer	7.91e-07	4.45e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—EGFR—esophageal cancer	7.91e-07	4.45e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—EGFR—esophageal cancer	7.89e-07	4.44e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NOS3—esophageal cancer	7.87e-07	4.43e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EP300—esophageal cancer	7.86e-07	4.42e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CDKN1A—esophageal cancer	7.83e-07	4.41e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—CDKN1A—esophageal cancer	7.8e-07	4.39e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MYC—esophageal cancer	7.8e-07	4.39e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NOTCH1—esophageal cancer	7.78e-07	4.38e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—EGFR—esophageal cancer	7.72e-07	4.35e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—EP300—esophageal cancer	7.71e-07	4.34e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NOS3—esophageal cancer	7.7e-07	4.33e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—EGFR—esophageal cancer	7.69e-07	4.33e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—PIK3CA—esophageal cancer	7.68e-07	4.32e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALDOB—esophageal cancer	7.67e-07	4.32e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HIF1A—esophageal cancer	7.64e-07	4.3e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—MYC—esophageal cancer	7.63e-07	4.29e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—EGFR—esophageal cancer	7.63e-07	4.29e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CCND1—esophageal cancer	7.62e-07	4.29e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—EGFR—esophageal cancer	7.6e-07	4.28e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NOS3—esophageal cancer	7.58e-07	4.27e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—EGFR—esophageal cancer	7.56e-07	4.26e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CYP19A1—esophageal cancer	7.54e-07	4.25e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NOS3—esophageal cancer	7.54e-07	4.24e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—ERBB2—esophageal cancer	7.54e-07	4.24e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—PIK3CA—esophageal cancer	7.51e-07	4.23e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—CDKN1A—esophageal cancer	7.48e-07	4.21e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—ERBB2—esophageal cancer	7.46e-07	4.2e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—EGFR—esophageal cancer	7.46e-07	4.2e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EP300—esophageal cancer	7.45e-07	4.19e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—MYC—esophageal cancer	7.45e-07	4.19e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—EP300—esophageal cancer	7.43e-07	4.18e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—PIK3CA—esophageal cancer	7.4e-07	4.17e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GAPDH—esophageal cancer	7.38e-07	4.16e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CDKN1A—esophageal cancer	7.37e-07	4.15e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—ERBB2—esophageal cancer	7.36e-07	4.14e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CRABP1—esophageal cancer	7.32e-07	4.12e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CREBBP—esophageal cancer	7.32e-07	4.12e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KDR—esophageal cancer	7.31e-07	4.11e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PTGS2—esophageal cancer	7.3e-07	4.11e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—EGFR—esophageal cancer	7.28e-07	4.1e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—esophageal cancer	7.26e-07	4.09e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—CDKN1A—esophageal cancer	7.21e-07	4.06e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—ERBB2—esophageal cancer	7.2e-07	4.05e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—PIK3CA—esophageal cancer	7.18e-07	4.04e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—MYC—esophageal cancer	7.18e-07	4.04e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—esophageal cancer	7.16e-07	4.03e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MYC—esophageal cancer	7.14e-07	4.02e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—PIK3CA—esophageal cancer	7.13e-07	4.01e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—EP300—esophageal cancer	7.11e-07	4.01e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—ERBB2—esophageal cancer	7.09e-07	3.99e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—ERBB2—esophageal cancer	7.05e-07	3.97e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CREBBP—esophageal cancer	7.05e-07	3.97e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—EGFR—esophageal cancer	7.02e-07	3.95e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EP300—esophageal cancer	7.02e-07	3.95e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—PIK3CA—esophageal cancer	7.01e-07	3.95e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EGFR—esophageal cancer	6.98e-07	3.93e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GNG7—esophageal cancer	6.96e-07	3.92e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MYC—esophageal cancer	6.94e-07	3.91e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—CDKN1A—esophageal cancer	6.91e-07	3.89e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—esophageal cancer	6.9e-07	3.88e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—HMOX1—esophageal cancer	6.88e-07	3.87e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOTCH1—esophageal cancer	6.88e-07	3.87e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—PIK3CA—esophageal cancer	6.87e-07	3.87e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—PIK3CA—esophageal cancer	6.87e-07	3.87e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EP300—esophageal cancer	6.86e-07	3.86e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MYC—esophageal cancer	6.85e-07	3.85e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—PIK3CA—esophageal cancer	6.85e-07	3.85e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EGFR—esophageal cancer	6.79e-07	3.82e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—PIK3CA—esophageal cancer	6.7e-07	3.77e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EGFR—esophageal cancer	6.7e-07	3.77e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—PIK3CA—esophageal cancer	6.67e-07	3.76e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCND1—esophageal cancer	6.66e-07	3.75e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—esophageal cancer	6.64e-07	3.74e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—esophageal cancer	6.64e-07	3.74e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—PIK3CA—esophageal cancer	6.62e-07	3.73e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—PIK3CA—esophageal cancer	6.6e-07	3.71e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EP300—esophageal cancer	6.57e-07	3.7e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—PIK3CA—esophageal cancer	6.56e-07	3.69e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NOS3—esophageal cancer	6.55e-07	3.69e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALDH2—esophageal cancer	6.52e-07	3.67e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCND1—esophageal cancer	6.5e-07	3.66e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MYC—esophageal cancer	6.49e-07	3.65e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PIK3CA—esophageal cancer	6.48e-07	3.65e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CDKN1A—esophageal cancer	6.44e-07	3.63e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—esophageal cancer	6.4e-07	3.61e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CDKN1A—esophageal cancer	6.38e-07	3.59e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCND1—esophageal cancer	6.36e-07	3.58e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—esophageal cancer	6.35e-07	3.57e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—esophageal cancer	6.33e-07	3.56e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PIK3CA—esophageal cancer	6.32e-07	3.56e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NOS3—esophageal cancer	6.31e-07	3.55e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CDKN1A—esophageal cancer	6.29e-07	3.54e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCND1—esophageal cancer	6.27e-07	3.53e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CREBBP—esophageal cancer	6.24e-07	3.51e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—PIK3CA—esophageal cancer	6.24e-07	3.51e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCND1—esophageal cancer	6.23e-07	3.51e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTT1—esophageal cancer	6.2e-07	3.49e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—esophageal cancer	6.2e-07	3.49e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CDKN1A—esophageal cancer	6.16e-07	3.47e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	6.13e-07	3.45e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EP300—esophageal cancer	6.13e-07	3.45e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ERBB2—esophageal cancer	6.13e-07	3.45e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—esophageal cancer	6.11e-07	3.44e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—PIK3CA—esophageal cancer	6.09e-07	3.43e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EP300—esophageal cancer	6.07e-07	3.42e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CDKN1A—esophageal cancer	6.06e-07	3.41e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PIK3CA—esophageal cancer	6.06e-07	3.41e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CDKN1A—esophageal cancer	6.03e-07	3.39e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EP300—esophageal cancer	5.98e-07	3.37e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—esophageal cancer	5.98e-07	3.37e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—esophageal cancer	5.97e-07	3.36e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ERBB2—esophageal cancer	5.9e-07	3.32e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PIK3CA—esophageal cancer	5.89e-07	3.32e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EP300—esophageal cancer	5.86e-07	3.3e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—esophageal cancer	5.84e-07	3.29e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS1—esophageal cancer	5.81e-07	3.27e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ENO1—esophageal cancer	5.81e-07	3.27e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—esophageal cancer	5.81e-07	3.27e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EP300—esophageal cancer	5.77e-07	3.25e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EP300—esophageal cancer	5.74e-07	3.23e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PSME1—esophageal cancer	5.73e-07	3.22e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PSME2—esophageal cancer	5.73e-07	3.22e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—esophageal cancer	5.7e-07	3.21e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—esophageal cancer	5.7e-07	3.21e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—esophageal cancer	5.62e-07	3.16e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—esophageal cancer	5.6e-07	3.15e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOS3—esophageal cancer	5.59e-07	3.15e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—esophageal cancer	5.51e-07	3.1e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—esophageal cancer	5.49e-07	3.09e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—esophageal cancer	5.41e-07	3.05e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—esophageal cancer	5.34e-07	3.01e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—esophageal cancer	5.33e-07	3e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—esophageal cancer	5.29e-07	2.98e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—esophageal cancer	5.26e-07	2.96e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1A—esophageal cancer	5.24e-07	2.95e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—esophageal cancer	5.23e-07	2.94e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—esophageal cancer	5.23e-07	2.94e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—esophageal cancer	5.22e-07	2.94e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—esophageal cancer	5.21e-07	2.93e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—esophageal cancer	5.19e-07	2.92e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—esophageal cancer	5.17e-07	2.91e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—esophageal cancer	5.1e-07	2.87e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—esophageal cancer	5.1e-07	2.87e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—esophageal cancer	5.07e-07	2.86e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1A—esophageal cancer	5.05e-07	2.84e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—esophageal cancer	5.03e-07	2.83e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—esophageal cancer	5.02e-07	2.83e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—esophageal cancer	5e-07	2.81e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—esophageal cancer	4.99e-07	2.81e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—EP300—esophageal cancer	4.98e-07	2.8e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.94e-07	2.78e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—esophageal cancer	4.92e-07	2.77e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—esophageal cancer	4.89e-07	2.75e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—esophageal cancer	4.86e-07	2.74e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EP300—esophageal cancer	4.8e-07	2.7e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.65e-07	2.62e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—esophageal cancer	4.62e-07	2.6e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—esophageal cancer	4.54e-07	2.55e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—esophageal cancer	4.49e-07	2.53e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1A—esophageal cancer	4.47e-07	2.51e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—esophageal cancer	4.43e-07	2.49e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CREBBP—esophageal cancer	4.42e-07	2.49e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—esophageal cancer	4.39e-07	2.47e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—esophageal cancer	4.34e-07	2.44e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—esophageal cancer	4.33e-07	2.44e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—esophageal cancer	4.28e-07	2.41e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—esophageal cancer	4.27e-07	2.4e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EP300—esophageal cancer	4.25e-07	2.39e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—esophageal cancer	4.24e-07	2.39e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HMOX1—esophageal cancer	4.24e-07	2.39e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—esophageal cancer	4.19e-07	2.36e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—esophageal cancer	4.18e-07	2.36e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—esophageal cancer	4.13e-07	2.32e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—esophageal cancer	4.1e-07	2.31e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—esophageal cancer	4.09e-07	2.3e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ABCB1—esophageal cancer	4.07e-07	2.29e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NOS3—esophageal cancer	3.95e-07	2.23e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—esophageal cancer	3.7e-07	2.08e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—esophageal cancer	3.69e-07	2.07e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—esophageal cancer	3.62e-07	2.04e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—esophageal cancer	3.62e-07	2.04e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—esophageal cancer	3.57e-07	2.01e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—esophageal cancer	3.55e-07	2e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—esophageal cancer	3.44e-07	1.93e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—esophageal cancer	3.14e-07	1.77e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—esophageal cancer	3.04e-07	1.71e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—EP300—esophageal cancer	3.01e-07	1.69e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.72e-07	1.53e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NOS3—esophageal cancer	2.44e-07	1.37e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.23e-07	1.25e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.22e-07	1.25e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—EP300—esophageal cancer	1.85e-07	1.04e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.37e-07	7.72e-07	CbGpPWpGaD
